Mergers and acquisitions are part of the lifeblood of the pharmaceutical industry, as companies flex their pocketbooks to acquire pipelines and talent to bolster and complement their own programs. While there were significant moves during the past 12 months, 2021 was largely quieter than previous years.
One year ago, BioSpace reported that Warren Buffett’s Berkshire Hathaway Inc. was investing heavily in four pharmaceutical companies: Pfizer, Bristol Myers Squibb, AbbVie, and Merck & Co. This week, Berkshire announced that it has scaled back those investments and completely eliminated its stake in Merck.
Fingerpaint, biopharma’s global commercialization partner for analytics-enabled integrated solutions, was named to Adweek’s Fastest-Growing Agencies list.
Syneos Health, the only fully integrated biopharmaceutical solutions organization, announced the acquisition of RxDataScience, a leading healthcare-focused data analytics, data management and artificial intelligence (AI) company.
Investors Hand Disc Medicine $90 Million to Control Hematological Diseases Published: Sept. 2, 2021 By Heather McKenzie BioSpace A two-year-old biopharma company tackling rare blood diseases has received a […]
For more than 50 years, randomized controlled trials (RCTs) have been used by the biopharmaceutical industry and regulators to evaluate the efficacy and safety of new medications as well as medical products that are being repurposed for new uses. But regulators and biopharmaceutical companies are being pushed to modernize their approaches to expedite drug development, which has resulted in increased attention to potential contributions of real world evidence (RWE).
As the work force returns to the office, life science companies are having to take their stance on vaccine policy. Some have chosen a strict mandate, others a mandate with options, and others have yet to issue an edict.
Topline results from Outlook Therapeutics’ pivotal Phase III NORSE TWO safety and efficacy trial show the biopharmaceutical company’s ONS-5010/Lytenava (bevacizumab) significantly improved outcomes in patients with neovascular age-related macular degeneration.
Ipsen, a global biopharmaceutical firm that specializes in neuroscience, oncology and rare diseases, partnered with Exicure, a clinical-stage biotech company that develops treatments for neurological, inflammatory and genetic disorders, to create new therapies for Angelman syndrome (AS) and Huntington’s disease (HD).
BioSpace takes a look at the flurry of expansion activity in the life sciences industry as biopharma and diagnostic companies expand manufacturing sites.
